Clinical trial
Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in…
NCT00472290 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00472290 |
|---|---|
| Title | Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) |
| Official title | An Open Label Extension Study Evaluating the Safety of Long Term Dosing of Romiplostim in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Hematology, MDS, Myelodysplastic Syndromes, Thrombocytopenia |
| Intervention type | Drug |
| Interventions | Romiplostim (formerly AMG 531) |
| Enrollment | 72 |
| Start date | Apr 1, 2007 |
| Primary completion | Jul 18, 2011 |
| Completion | Dec 26, 2011 |
| First posted | May 11, 2007 |
| Last update posted | Dec 29, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: